pharmaceuticals
23 ARTICLES
Dr. Reddy’s wants to be India’s fifth largest drugmaker. What will it take?
The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.
09 Jun 2025
Why quick delivery of medicines will be difficult to scale
Quick-commerce apps are likely to run into regulations and poor order volumes as they try to grow this business.
14 Mar 2025
Indian pharma exporters protesting against new regulations is not a good look
The rules require exporters of certain drugs to get an NOC from importing countries—a small but much-needed step to restoring India’s credibility in the global pharma market.
12 Mar 2025
Aurobindo, Glenmark and Zydus recall products in the US market
All three Indian pharma companies have initiated the recall due to quality concerns.
15 Dec 2024
Why is Swiggy catching flak for its latest quick-delivery promise?
The food and grocery delivery company’s idea of providing prescription drugs in 10 minutes is facing resistance from traditional pharma players.
13 Nov 2024
Dr Reddy’s hit by a big recall in the US
The FDA flags manufacturing issues in multiple strengths of Cinacalcet tablets produced by the pharma major in India.
03 Nov 2024
Natco just can’t kick its high-risk, high-gain game plan
CEO Rajeev Nannapaneni’s oft-used strategy of mounting patent challenges in the US got the pharma company its latest blockbuster Revlimid. But what after sales fall off a cliff?
03 Oct 2024
Zydus Lifesciences pulled up by FDA over quality-control issues
The US health regulator, in a letter to the pharma company, accuses it of violating good manufacturing practices at its Vadodara plant.
15 Sept 2024
KKR set to hit the jackpot with JB Chemicals and Pharma
The investment giant is rumoured to be eyeing an exit with a 5x return, having taken the drugmaker from obscurity to a billion-dollar bidding war.
30 Aug 2024
For Sun Pharma’s Dilip Shanghvi, specialty drugs remain the magic bullet
Specialty drugs are fast becoming a lucrative market globally. And India’s largest drugmaker has done well to make the most of this opportunity so far. But it’s too soon to rest easy.
01 Aug 2024